Compare HSIC & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HSIC | ROIV |
|---|---|---|
| Founded | 1932 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 20.7B |
| IPO Year | 1996 | 2021 |
| Metric | HSIC | ROIV |
|---|---|---|
| Price | $78.04 | $29.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $84.50 | $27.56 |
| AVG Volume (30 Days) | 1.5M | ★ 5.9M |
| Earning Date | 05-26-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.21 | N/A |
| EPS | ★ 3.27 | N/A |
| Revenue | ★ $13,201,995,000.00 | $29,053,000.00 |
| Revenue This Year | $6.15 | N/A |
| Revenue Next Year | $3.62 | $385.85 |
| P/E Ratio | $23.81 | ★ N/A |
| Revenue Growth | ★ 5.94 | N/A |
| 52 Week Low | $60.56 | $8.73 |
| 52 Week High | $89.29 | $30.03 |
| Indicator | HSIC | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 66.48 |
| Support Level | $74.66 | $20.46 |
| Resistance Level | $79.37 | N/A |
| Average True Range (ATR) | 2.55 | 0.96 |
| MACD | -0.38 | -0.01 |
| Stochastic Oscillator | 17.36 | 84.62 |
Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.